William Rosenfeld, MD, AAN 2022: Phase III post-hoc analysis of cenobamate for focal-onset seizures

Cenobamate is approved in the United States for focal-onset seizures (partial-onset seizures) in adults both as adjunctive and monotherapy. In the EU, cenobamate is approved as adjunctive therapy for focal-onset seizures with or without secondary generalization for adult patients who have not been adequately controlled with at least two antiseizure medications. Dr. William Rosenfeld (Comprehensive Epilepsy Care Centre for Children and Adults, St. Louis, MO, USA) discusses pooled analysis of data investigating cenobamate for the treatment of focal-onset seizures and how the incidence of treatment-related cognitive and psychiatric events compare with other anti-seizure medications.  

The abstract entitled ‘Efficacy of Cenobamate by Focal Seizure Subtypes: Post-hoc Analysis of a Phase 3, Multicenter, Open-Label Study’ was presented at the American Academy of Neurology (AAN) annual meeting, April 2-7, 2022.

Questions:

1. Could you tell us a little about cenobamate, the pooled analysis of data you are presenting, and its findings? (0:07)
2. How did the incidence of cognitive and psychiatric treatment-related adverse events compare with that of other anti-seizure medications? (7:46)
3. What are your take home messages? (16:15)

Disclosures: William Rosenfeld is a consultant for Arvelle and SK Life Science, Inc.; receives grant/research support from SK Life Science, Inc., and UCB Pharma; and receives honoraria/honorarium from SK Life Science, Inc.

Support:  Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Filmed as a highlight of AAN 2022